Non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are the leading cause of morbidity and mortality from cardiovascular disease worldwide. The American Heart Association/American College of Cardiology and the European Society of Cardiology periodically release practice guidelines to guide clinicians in the management of NSTE-ACS, most recently in in 2014 and 2015, respectively. The present review compares and contrasts the 2 guidelines, with a focus on the strength of recommendation and level of evidence in the approach to initial presentation and diagnosis of NSTE-ACS, risk assessment, treatments, and systems of care. Important differences include the use of a rapid rule-out protocol with high-sensitivity troponin assays, a preference for prasugrel/ticagrelor and fondaparinux for anticoagulation therapy, and a preference for radial arterial access in the European Society of Cardiology guidelines compared with the American Heart Association/American College of Cardiology guidelines. We also highlight the similarities and differences in the guidelines for special patient populations and suggest areas of further study. 
GUIDELINES AND LEVEL OF EVIDENCE
All GWC members must disclose conflicts of interest before initiation of the writing effort. The ACC/AHA policy on relationships with industry requires that at least 50% of writing committee members, plus the Chair, have no relevant relationships (3) . The ESC policy requires that GWC members report all potential conflicts, both perceived and real, before being appointed to the task force (4).
SUMMARY INFORMATION
Substantial resources are required to prepare and revise practice guidelines. The assimilation of the data, review and interpretation, writing, and revisions after peer review are laborious and timeconsuming, particularly in disease states such as ACS for which extensive research efforts exist. Table 3 presents some overall data that compare and contrast logistical and procedural similarities and differences. Both guidelines also stress the growing importance of biomarkers, namely high-sensitivity cardiac troponin (hs-cTN) assays, due to their high negative predictive value for ACS (5, 6) . In particular, the ESC guidelines recommend utilizing a shortened algorithm for diagnosis of NSTE-ACS, with the use of a 0 h/3 h or 0 h/1 h algorithm measurement of hs-cTN. In large validation cohorts, the negative predictive value of such an approach exceeded 98% (2, 7, 8) . The 2015 ESC guidelines also recommend assessment of copeptin, the C-terminal part of the vasopressin prohormone, for added sensitivity in ruling out acute myocardial infarctions, particularly when hs-cTN assays are not readily available (9) (10) (11) . In patients with suspected NSTE-ACS without recurrence of chest pain and with normal levels of cardiac troponin, the ESC guidelines recommend a noninvasive stress test with imaging to look for inducible ischemia (COR I, LOE A) before deciding on an invasive strategy (17) (18) (19) . In contrast, the AHA/ACC guidelines provide a lower strength of recommenda- Assess Strategies in Ischemic Syndromes) data; according to these data, there were no differences between patients with ACS undergoing an early invasive strategy using a higher dose (300 to 325 mg/day) compared with those taking a lower dose (75 to 100 mg/day) of aspirin (24).
The AHA/ACC guidelines recommend either clopidogrel or ticagrelor loading for either the invasive or ischemia-guided options, with a COR IIa, LOE B recommendation for ticagrelor over clopidogrel. The guidelines recommend prasugrel when a PCI is planned in those not at high risk of bleeding, suggesting that older patients benefit more than younger patients with an early invasive strategy.
Other studies corroborate the benefit of an early invasive strategy in older patients (56) (57) (58) , with the caveat that older patients experience a 3-fold higher bleeding risk (59) . guidelines for management of NSTE-ACS offer comprehensive reviews of the available evidence as a guide for health care providers with many commonalities but also some important differences.
